Thinklab Cancer

The top 50 thought leaders in cancer research: thinklab.com/c/cancer-resea… (Follow this account for retweets of aggregated top stories)

@EJonasch @MDAndersonNews & team in @TheLancetOncol —> Pazopanib has promising activity in von Hippel-Lindau disease @VHLAlliance: may be useful in those with growing lesions or to reduce the size of unresectable lesions. bit.ly/2MHyFPn @montypal @OncHahn @PauloBergerot

Criteria for High Risk Smoldering Myeloma. Also see Revised Mayo 20-2-20 risk stratification (20%BMPC, 2g/dL M protein, 20 FLC ratio) #myelomaVR @MayoMyeloma @mtmdphd @MyelomaTeacher onlinelibrary.wiley.com/doi/10.1002/aj…

Very nice analysis by the Wash U group showing persistence of disease-associated mutations at day +30 post allogeneic transplantation are predictive of PFS and relapse risk in MDS patients. #bmtsm #leusm nejm.org/doi/full/10.10…

Big news just in...Combo of PD-L1 inh. Avelumab + TKI axitinib is the 1st + IO/TKI PIII that met PFS 1*endpoint irrespective of PD-L1! ⁦@pfizer⁩ ⁦@DanaFarber⁩ ⁦@kcCURE⁩ ⁦@IKCCorg⁩ ⁦@KidneyCancer⁩ Great day for RCC patients! markets.businessinsider.com/news/stocks/ba…

Our current approach to #cancer treatment, despite some modest improvements, is still far from precise. @LizSzabo @KHNews gets real & reminds us of the long road ahead. nytimes.com/2018/09/11/opi… @nytopinion

He is analytical and reflective, a lofty dreamer. She will joke and kvetch and needle. Together they have made a life together — and together they are confronting the unthinkable. buff.ly/2LXITec

Provocative article @TheLancetOncol RCTs are being done with the aim of gaining regulatory authorisation, while testing trivial clinical questions. Hence the importance of academics trials thelancet.com/journals/lanon…

MET exon 14-altered lung cancers express PD-L1, but TMB is low and few responses to PD-1 blockade. ⁦@Annals_Oncology⁩ academic.oup.com/annonc/advance…

She’s worn both a hospital gown and a white coat. Now she wants to change how doctors perceive... statnews.com/2018/08/31/she… via @statnews

Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials ja.ma/2LIfHYr

It's high time to transcend @usnews ratings and move to indvidualized ratings of hospitals nejm.org/doi/full/10.10… rand.org/health/project… @NEJM by @MWFriedberg @RANDCorporation @minhealthnz @BrighamWomens

UK rejects Gilead's CAR-T cancer cell therapy as too expensive reut.rs/2P9zeDo

Announcing the 2018 Class of PCF Young Investigators! We are so proud to fund these amazing early career scientists who have dedicated their careers to ending #ProstateCancer! #PCFfunded @PCFnews @manyvscancer pcf.org/news/the-prost…

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (Miao et al.) go.nature.com/2oditLV

The #1 supplement—fish oil—taken by tens of millions Americans for billions of dollars/yr. And the latest trial to debunk any value in them. nejm.org/doi/full/10.10… @NEJM #ESCCongress

McCain said in a statement that he has surpassed expectations for his survival since his diagnosis. "But the progress of disease and the inexorable advance of age render their verdict," and the senator has decided to end medical treatment. wapo.st/2wn2Ipp

SOLAR-1 Trial (PI3-k Inh. Alpelisib in Metastatic Breast Cancer) met primary endpont of PFS. Key things to look when data is reported(likely #ESMO18 ): 1. Toxicity profile 2. Magnitude of diff. in PFS 3. Efficacy in CDK4/6 tx patients 4. PI3k test profile novartis.com/news/media-rel…

Proud to be part of this groundbreaking work & awesome collaborative group / @NEJM / #Melanoma brain metastasis can be definitively teated w #immunotherapy marking a new era in #Immunooncology #Cancerresearch nejm.org/doi/full/10.10… @CleClinicMD #CleClinicCancer @caseccc

Our work on Steroids and PD-(L)1 Blockade. This is not randomized data, and pts that need steroids have probably a poorer prognosis (because of symptomatic brain or bone mets, recent radiotherapy...). Pts should receive IO when indicated, even w steroids. ascopubs.org/doi/full/10.12…